| Anticoagulants: a review of the pharmacology, dosing, and complications M Alquwaizani, L Buckley, C Adams, J Fanikos Current emergency and hospital medicine reports 1, 83-97, 2013 | 219 | 2013 |
| Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial) BW Van Tassell, J Canada, S Carbone, C Trankle, L Buckley, ... Circulation: Heart Failure 10 (11), e004373, 2017 | 186 | 2017 |
| Effects of sodium‐glucose cotransporter 2 inhibitors on 24‐hour ambulatory blood pressure: a systematic review and meta‐analysis WL Baker, LF Buckley, MS Kelly, JD Bucheit, ED Parod, R Brown, ... Journal of the American Heart Association 6 (5), e005686, 2017 | 185 | 2017 |
| Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis J Torrado, L Buckley, A Durán, P Trujillo, S Toldo, J Valle Raleigh, ... Journal of the American College of Cardiology 71 (15), 1676-1695, 2018 | 182 | 2018 |
| Interleukin‐1 blockade inhibits the acute inflammatory response in patients with ST‐segment–elevation myocardial infarction A Abbate, CR Trankle, LF Buckley, MJ Lipinski, D Appleton, D Kadariya, ... Journal of the American Heart Association 9 (5), e014941, 2020 | 181 | 2020 |
| Interleukin-1 blockade in cardiovascular diseases: a clinical update LF Buckley, A Abbate European heart journal 39 (22), 2063-2069, 2018 | 169 | 2018 |
| IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction: Results From DHART2 BW Van Tassell, CR Trankle, JM Canada, S Carbone, L Buckley, ... Circulation: Heart Failure 11 (8), e005036, 2018 | 147 | 2018 |
| Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study BW Van Tassell, NA Abouzaki, CO Erdle, S Carbone, CR Trankle, ... Journal of cardiovascular pharmacology 67 (6), 544-551, 2016 | 122 | 2016 |
| Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP LF Buckley, DL Dixon, GF Wohlford IV, DS Wijesinghe, WL Baker, ... Diabetes Care 40 (12), 1733-1738, 2017 | 119 | 2017 |
| Interleukin‐1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D‐HART2) BW Van Tassell, LF Buckley, S Carbone, CR Trankle, JM Canada, ... Clinical cardiology 40 (9), 626-632, 2017 | 116 | 2017 |
| Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit LF Buckley, DM Carter, L Matta, JW Cheng, C Stevens, RM Belenkiy, ... JACC: Heart Failure 4 (1), 1-8, 2016 | 102 | 2016 |
| Targeting the NLRP3 inflammasome in cardiovascular diseases S Toldo, E Mezzaroma, LF Buckley, N Potere, M Di Nisio, G Biondi-Zoccai, ... Pharmacology & therapeutics 236, 108053, 2022 | 101 | 2022 |
| Dietary fat, sugar consumption, and cardiorespiratory fitness in patients with heart failure with preserved ejection fraction S Carbone, JM Canada, LF Buckley, CR Trankle, HE Billingsley, ... Basic to Translational Science 2 (5), 513-525, 2017 | 98 | 2017 |
| Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension N Fatani, DL Dixon, BW Van Tassell, J Fanikos, LF Buckley Journal of the American College of Cardiology 77 (10), 1290-1299, 2021 | 81 | 2021 |
| Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction S Carbone, LF Buckley, CR Trankle, DL Dixon, R Buzzetti, R Arena, ... Journal of the American College of Cardiology 68 (22), 2487-2488, 2016 | 58 | 2016 |
| Interleukin-1 Blockade for the Treatment of Pericarditis L Buckley, MM Viscusi, B Van Tassell, A Abbate European Heart Journal-Cardiovascular Pharmacotherapy, 2017 | 55 | 2017 |
| Role for anti-cytokine therapies in severe coronavirus disease 2019 LF Buckley, GF Wohlford, C Ting, A Alahmed, BW Van Tassell, A Abbate, ... Critical care explorations 2 (8), e0178, 2020 | 54 | 2020 |
| Low NT‐proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction LF Buckley, JM Canada, MG Del Buono, S Carbone, CR Trankle, ... ESC heart failure 5 (2), 372-378, 2018 | 53 | 2018 |
| A review of PCSK9 inhibition and its effects beyond LDL receptors DL Dixon, C Trankle, L Buckley, E Parod, S Carbone, BW Van Tassell, ... Journal of clinical lipidology 10 (5), 1073-1080, 2016 | 53 | 2016 |
| Vorapaxar: the current role and future directions of a novel protease-activated receptor antagonist for risk reduction in atherosclerotic disease RJ Gryka, LF Buckley, SM Anderson Drugs in R&D 17, 65-72, 2017 | 52 | 2017 |
